Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
03 déc. 2024 07h00 HE
|
Chemomab Therapeutics
Chemomab management is participating in the Oppenheimer Movers in Rare Disease Summit on Dec 13, 2024 at the Westin Grand Central in NYC.
Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
14 nov. 2024 07h00 HE
|
Chemomab Therapeutics
In 3Q reported positive CM-101 PSC Ph 2 results. On track for 2 milestones in Q125--FDA agreement on PSC Ph 3 design and Ph 2 open label extension readout.
Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update
30 oct. 2024 07h00 HE
|
Chemomab Therapeutics
Chemomab will report 3Q 2024 financial results and provide a corporate update on November 14, 2024 at 7am ET.
Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024
15 oct. 2024 07h00 HE
|
Chemomab Therapeutics
Chemomab announces late-breaking oral presentation of CM-101 Phase 2 results in primary sclerosing cholangitis patients at 2024 AASLD The Liver Meeting
Chemomab Therapeutics to Present at October 2024 Investor Conferences
01 oct. 2024 07h00 HE
|
Chemomab Therapeutics
Chemomab will participate in the ROTH Healthcare Opportunities Conference in NYC on Oct 9 and the Maxim Healthcare Virtual Summit on Oct 16 at 9am ET.
Chemomab Therapeutics to Present at September 2024 Investor Conferences
28 août 2024 07h00 HE
|
Chemomab Therapeutics
Chemomab will be presenting at the HC Wainwright Global Investment Conference and the HBM Biopharma Summit in September
Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update
21 août 2024 07h00 HE
|
Chemomab Therapeutics
Ph 2 PSC data showed safety/activity supporting advancing CM-101 to Ph 3. New financing extends cash runway to early 2026. 2 milestones on track for 1Q25.
Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update
12 août 2024 07h00 HE
|
Chemomab Therapeutics
Chemomab will report its second quarter 2024 financial results and provide a business update on August 21, 2024 at 7:00am ET.
Chemomab Therapeutics Announces Closing of $10 Million Private Placement
30 juil. 2024 09h00 HE
|
Chemomab Therapeutics
Chemomab closed a $10 million PIPE financing that included new and existing top tier investors and extends the cash runway through the beginning of 2026
Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
26 juil. 2024 07h00 HE
|
Chemomab Therapeutics
Chemomab has regained full compliance with the Nasdaq minimum bid price rule